Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carilex MedicalROCO:7726 42 Debt-to-EBITDA is 2.60 as of Jun. 2026, which is 110% above its 10-year median of 1.24. GuruFocus rates ROCO:7726 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Carilex Medical ranks worse than 92.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Carilex Medical's Debt-to-EBITDA or its related term are showing as below:
ROCO:7726'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -31.71 Med: 1.24 Max: 8.9
Current: 8.9
During the past 6 years, the highest Debt-to-EBITDA Ratio of Carilex Medical was 8.90. The lowest was -31.71. And the median was 1.24.
ROCO:7726's Debt-to-EBITDA is ranked worse than 92.14% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs ROCO:7726: 8.90
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Carilex Medical Debt-to-EBITDA Related Terms
Carilex Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Carilex Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7726 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Carilex Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carilex Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Carilex Medical (ROCO:7726) has a Debt-to-EBITDA of 2.60 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carilex Medical. This is 110% above median its historical median of 1.24. According to the industry distribution chart, Carilex Medical ranks #434 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 92.1%.
Is Carilex Medical's Debt-to-EBITDA too high?
Carilex Medical's current Debt-to-EBITDA of 2.60 is 110% above median its 10-year median of 1.24. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Carilex Medical's value of 2.60 is 59.5% above this industry median. Based on the distribution chart, Carilex Medical ranks #434 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carilex Medical has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #434 out of 471 companies for Debt-to-EBITDA. This places Carilex Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Carilex Medical's value of 2.60 is 59.5% above this benchmark. While the company's 10-year median is 1.24 vs. the industry median of 1.63, Carilex Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carilex Medical's current Debt-to-EBITDA of 2.60 is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carilex Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carilex Medical's current Debt-to-EBITDA is 2.60, which is 110% above median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current Debt-to-EBITDA of 2.60. The current Debt-to-EBITDA is 2.60, which is 110% above median its 10-year median of 1.24 and 59.5% above the Medical Devices & Instruments industry median of 1.63. Carilex Medical's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current Debt-to-EBITDA is 2.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
42GF Score
Get the complete analysis for ROCO:7726
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
